Volume 27, Number 3—March 2021
Research
Oral Human Papillomavirus Infection in Children during the First 6 Years of Life, Finland
Stina Syrjänen
, Marjut Rintala, Marja Sarkola, Jaana Willberg, Jaana Rautava, Hanna Koskimaa, Anna Paaso, Kari Syrjänen, Seija Grénman1, and Karolina Louvanto1
, Marjut Rintala, Marja Sarkola, Jaana Willberg, Jaana Rautava, Hanna Koskimaa, Anna Paaso, Kari Syrjänen, Seija Grénman1, and Karolina Louvanto1
Table 2
Duration of genotype and species-specific persistence of oral HPV infection in children*
| HPV genotypes/clades |
No. |
Mean persistence, mo (range) |
| HPV6 | 2 | 19.7 (1.8–37.5) |
| HPV16 | 36 | 19.8 (0.1–82) |
| HPV18 | 3 | 11.8 (5.0–18.6) |
| HPV31 | 1 | 92.2 (92.2) |
| HPV33 | 3 | 14.2 (1.0–40.6) |
| HPV39 | 1 | 89.0 (89.0) |
| HPV58 | 1 | 88.7 (88.7) |
| Multiple-type infections (>2) | 20 | 14.2 (1.0–91.0) |
| Clade A7: HPV18, 39, 45, 59, 68, 70, 85 | 4 | 31.2 (5.0–89.0) |
| Clade A9: HPV16, 31, 33, 35, 52, 58 | 41 | 22.8 (0.1–92.2) |
| Clade A10: HPV6, 11, 13, 44, 55, 74 | 2 | 19.7 (1.8–37.7) |
*Persistence is defined as having >2 consecutive visit HPV-positive results for the same HPV genotype or clade. HPV, human papillomavirus.
1These senior authors contributed equally to this article.
Page created: December 22, 2020
Page updated: February 21, 2021
Page reviewed: February 21, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.